Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Margetuximab plus chemotherapy in Chinese patients with HER2+ metastatic breast cancer
NCT04398108Phase 1Completed
- Sponsor
- Zai Lab
- Start
- Aug 2020
- Primary completion
- Apr 2021
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of margetuximab in HER2-positive breast cancer, sponsored by Zai Lab. Primary endpoints: Maximum Plasma Concentration at 18 months, Time to Maximum Plasma Concentration at 18 months and 2 more. Started Aug 2020; status: completed.
02
Drugs
margetuximab
03
Conditions
HER2-positive breast cancer
Beyond the preview
Go deeper on NCT04398108.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04398108.